Trial Profile
A Phase III Randomized Study of EC Followed by Paclitaxel Versus FEC Followed by Paclitaxel, All Given Either Every 3 Weeks or 2 Weeks Supported by Pegfilgrastim, for Node Positive Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel; Trastuzumab
- Indications Carcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms GIM2
- 09 Nov 2022 Primary endpoint (Disease-free survival (DFS) dose-dense interval group than the standard-interval group) has been met, according to Results published in the Lancet Oncology.
- 09 Nov 2022 Primary endpoint (Disease-free survival (DFS) between FEC-P and EC-P groups ) has not been met, according to Results published in the Lancet Oncology.
- 09 Nov 2022 Results assessing long-term results of the study, published in the Lancet Oncology.